Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J McPhee

Showing results (281-290 of 298) with videos related to

Pageof 30
Sort By:
BMJ Open|February 7, 2021
Protocol for assessing whether cognition of preterm infants <29 weeks' gestation can be improved by an intervention with the omega-3 long-chain polyunsaturated fatty acid docosahexaenoic acid (DHA): a follow-up of a randomised controlled trialJacqueline F Gould, Maria Makrides, Thomas R Sullivan, et al.
Science Translational Medicine|December 21, 2012
Long-term follow-up after gene therapy for canavan diseasePaola Leone, David Shera, Scott W J McPhee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 10, 2011
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vectorDawn E Bowles, Scott W J McPhee, Chengwen Li, et al.
Human Gene Therapy|November 25, 2014
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trialPaul E Monahan, Junjiang Sun, Tong Gui, et al.
BMJ Open|March 20, 2015
Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trialCarmel T Collins, Robert A Gibson, Peter J Anderson, et al.
The American Journal of Clinical Nutrition|May 10, 2019
Docosahexaenoic acid supplementation of preterm infants and parent-reported symptoms of allergic disease at 7 years corrected age: follow-up of a randomized controlled trialAnoja W Gunaratne, Maria Makrides, Carmel T Collins, et al.
The New England Journal of Medicine|October 27, 2022
Neonatal Docosahexaenoic Acid in Preterm Infants and Intelligence at 5 YearsJacqueline F Gould, Maria Makrides, Robert A Gibson, et al.
JAMA Network Open|June 9, 2023
Mediation Analysis to Untangle Opposing Associations of High-Dose Docosahexaenoic Acid With IQ and Bronchopulmonary Dysplasia in Children Born PretermThomas R Sullivan, Jacqueline F Gould, Jana M Bednarz, et al.
BMJ Open|May 10, 2023
Prenatal iodine supplementation and early childhood neurodevelopment: the PoppiE trial - study protocol for a multicentre randomised controlled trialKaren P Best, Jacqueline F Gould, Maria Makrides, et al.
Blood|October 17, 2020
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expressionBarbara A Konkle, Christopher E Walsh, Miguel A Escobar, et al.
Pageof 30

Showing results (281-290 of 298) with videos related to

Sort By:
Pageof 30
BMJ Open|February 7, 2021
Protocol for assessing whether cognition of preterm infants <29 weeks' gestation can be improved by an intervention with the omega-3 long-chain polyunsaturated fatty acid docosahexaenoic acid (DHA): a follow-up of a randomised controlled trialJacqueline F Gould, Maria Makrides, Thomas R Sullivan, et al.
Science Translational Medicine|December 21, 2012
Long-term follow-up after gene therapy for canavan diseasePaola Leone, David Shera, Scott W J McPhee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 10, 2011
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vectorDawn E Bowles, Scott W J McPhee, Chengwen Li, et al.
Human Gene Therapy|November 25, 2014
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trialPaul E Monahan, Junjiang Sun, Tong Gui, et al.
BMJ Open|March 20, 2015
Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trialCarmel T Collins, Robert A Gibson, Peter J Anderson, et al.
The American Journal of Clinical Nutrition|May 10, 2019
Docosahexaenoic acid supplementation of preterm infants and parent-reported symptoms of allergic disease at 7 years corrected age: follow-up of a randomized controlled trialAnoja W Gunaratne, Maria Makrides, Carmel T Collins, et al.
The New England Journal of Medicine|October 27, 2022
Neonatal Docosahexaenoic Acid in Preterm Infants and Intelligence at 5 YearsJacqueline F Gould, Maria Makrides, Robert A Gibson, et al.
JAMA Network Open|June 9, 2023
Mediation Analysis to Untangle Opposing Associations of High-Dose Docosahexaenoic Acid With IQ and Bronchopulmonary Dysplasia in Children Born PretermThomas R Sullivan, Jacqueline F Gould, Jana M Bednarz, et al.
BMJ Open|May 10, 2023
Prenatal iodine supplementation and early childhood neurodevelopment: the PoppiE trial - study protocol for a multicentre randomised controlled trialKaren P Best, Jacqueline F Gould, Maria Makrides, et al.
Blood|October 17, 2020
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expressionBarbara A Konkle, Christopher E Walsh, Miguel A Escobar, et al.
Pageof 30